A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Single-Dose Pharmacokinetics of MK0462 in Subjects With Migraines Aged 6 to 17 Years.
Phase of Trial: Phase I
Latest Information Update: 09 Jun 2017
At a glance
- Drugs Rizatriptan (Primary)
- Indications Migraine
- Focus Adverse reactions
- Sponsors Merck & Co
- 30 Jan 2012 Results published in the Headache.
- 05 Nov 2010 Actual end date changed from Jun 2008 to Sep 2010 as reported by ClinicalTrials.gov.
- 27 Jun 2010 Saftey and pharmacokinetic outcomes were reported at the 52nd Annual Scientific Meeting of the American Headache Society.